Maria Chiara Sergi, Researcher at Bari San Paolo, shared a post on LinkedIn:
“Honored to have presented, during the AIOM | The ITALIAN ASSOCIATION of Medical Oncology Congress, the results of our international retrospective study on patients with melanoma brain metastases (MBM) treated with COMBO with or without concomitant or sequential SRT.
The therapeutic landscape for optimizing treatment strategies in these patients is continuously evolving: our work, recently published in EJC, suggests the benefit of SRT in patients with MBM, regardless of treatment timing.
I’m truly grateful to prof. Mario Mandalà for this opportunity.”
More posts featuring AIOM25 on OncoDaily.